Topoisomerase I-directed Anticancer Drugs
Topoisomerase I-directed Anticancer Drugs
批准号:
6437280
负责人:
LEROY F LIU
金额:
$27.95万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-04-01 至 2004-12-31
中文摘要
人DNA拓扑异构酶I (hTOP1)是喜树碱(CPTs)等抗癌药物高效的新分子靶点。CPTs通过捕获共价反应中间体(三元TOP1可切割复合物)来抑制(毒害)TOP1。这些TOP1可切割复合物代表了一种新型的细胞病变,对肿瘤细胞具有高效的杀伤作用。除了cpt外,越来越多的化合物(TOP1毒物)(如吲哚咔唑、硝基嘌呤、saintopin、morpholinyl doxorubicin、aclacinomycin a、indino [1,2-c]异喹啉、nogalamycin、放线菌素D、原小檗碱、二苯并[c,h]喹啉、2-苯基苯并咪唑和特苯并咪唑)已被发现可诱导TOP1可切割配合物。尽管TOP1可切割复合物在肿瘤细胞杀伤中具有明确的重要性,但TOP1毒物杀伤肿瘤细胞的分子机制尚不清楚。我们的初步研究表明,至少有两种不同的分子机制可能参与了这些不同的TOP1毒物捕获TOP1可切割复合物的过程。CPTs是典型的TOP1毒物,通过特异性抑制TOP1催化的断裂/宗教反应的宗教步骤来捕获TOP1可切割复合物,可能是通过在DNA切割位点与TOP1- DNA复合物结合(宗教阻断剂)。相比之下,诺加霉素是一种DNA结合剂,具有插入性和较小的凹槽定向相互作用模式,通过诱导远端DNA弯曲来捕获TOP1可切割复合物,这有利于TOP1结合/切割(切割增强剂)。不同TOP1毒物引起TOP1中毒的两种不同模式的鉴定可能为药物设计和开发提供新的机会。在目前的应用中,我们计划对这两种TOP1中毒模式进行表征,并探讨不同TOP1中毒诱导的差异生物学反应。具体目的是:(1)以诺加霉素为模型,建立TOP1切割增强子的DNA曲率模型;(2)探讨不同TOP1毒物诱导的TOP1可切割复合物的蛋白质构象和细胞修饰。
英文摘要
Human DNA topoisomerase I (hTOP1) is a highly effective new molecular target for anticancer drugs such as camptothecins (CPTs). CPTs inhibit (poison) TOP1 by trapping a covalent reaction intermediate, the ternary TOP1 cleavable complex. These TOP1 cleavable complexes represent a new type of cellular lesion highly effective in killing tumor cells. In addition to CPTs, a growing list of compounds (TOP1 poisons) (e.g. indolocarbazoles, nitidines, saintopin, morpholinyl doxorubicin, aclacinomycin A, indeno[1,2-c]isoquinolines, nogalamycin, actinomycin D, protoberberines, dibenzo[c,h]cinnolines, 2-phenylbenzimidazoles and terbenzimidazoles) have been identified to induce TOP1 cleavable complexes. Despite the clear importance of TOP1 cleavable complexes in tumor cell killing, the molecular mechanism underlying tumor cell killing by TOP1 poisons remains unclear. Our preliminary studies have suggested that at least two distinct molecular mechanisms may be involved in trapping TOP1 cleavable complexes by these different TOP1 poisons. CPTs, the prototypic TOP1 poisons, trap TOP1 cleavable complexes by specifically inhibiting the religation step of the TOP1-catalyzed breakage/religation reaction, presumably by binding to the TOP1- DNA complex at the site of DNA cleavage (religation blockers). By contrast, nogalamycin, a DNA binder with both intercalative and minor groove-directed modes of interactions, traps TOP1 cleavable complexes by inducing a distal DNA bend which favors TOP1 binding/cleavage (cleavage enhancers). The identification of two distinct modes of TOP1 poisoning by different TOP1 poisons may offer new opportunities for drug design and development. In the current application, we plan to characterize these two modes of TOP1 poisoning and to probe the differential biological responses induced by different TOP1 poisons. The specific aims are (1) to establish a DNA curvature model for TOP1 cleavage enhancers using nogalamycin as a model, and (2) to probe the protein conformation and cellular modification of TOP1 cleavable complexes induced by different TOP1 poisons.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Training in Cancer Pharmacology
-
批准号:7128170
-
项目类别:
-
资助金额:$36.81万
-
财政年份:2005
-
负责人:LEROY F LIU
-
依托单位:
Training in Cancer Pharmacology
-
批准号:6894915
-
项目类别:
-
资助金额:$18.16万
-
财政年份:2005
-
负责人:LEROY F LIU
-
依托单位:
Training in Cancer Pharmacology
-
批准号:7292666
-
项目类别:
-
资助金额:$32.99万
-
财政年份:2005
-
负责人:LEROY F LIU
-
依托单位:
Training in Cancer Pharmacology
-
批准号:7498567
-
项目类别:
-
资助金额:$27.63万
-
财政年份:2005
-
负责人:LEROY F LIU
-
依托单位:
Training in Cancer Pharmacology
-
批准号:7681012
-
项目类别:
-
资助金额:$12.94万
-
财政年份:2005
-
负责人:LEROY F LIU
-
依托单位:
Mechanism of Action of TOP2-Directed Anticancer Drugs
-
批准号:8129544
-
项目类别:
-
资助金额:$29.5万
-
财政年份:2004
-
负责人:LEROY F LIU
-
依托单位:
Mechanism of Action of TOP2-Directed Anticancer Drugs
-
批准号:7526710
-
项目类别:
-
资助金额:$28.11万
-
财政年份:2004
-
负责人:LEROY F LIU
-
依托单位:
Mechanism of action of TOP2-directed anticancer drugs
-
批准号:7006957
-
项目类别:
-
资助金额:$28.02万
-
财政年份:2004
-
负责人:LEROY F LIU
-
依托单位:
Mechanism of action of TOP2-directed anticancer drugs
-
批准号:6782758
-
项目类别:
-
资助金额:$28.69万
-
财政年份:2004
-
负责人:LEROY F LIU
-
依托单位:
Mechanism of Action of TOP2-Directed Anticancer Drugs
-
批准号:8307026
-
项目类别:
-
资助金额:$23.21万
-
财政年份:2004
-
负责人:LEROY F LIU
-
依托单位:
Mechanism of Action of TOP2-Directed Anticancer Drugs
-
批准号:7669433
-
项目类别:
-
资助金额:$28.95万
-
财政年份:2004
-
负责人:LEROY F LIU
-
依托单位:
Mechanism of Action of TOP2-Directed Anticancer Drugs
-
批准号:7869327
-
项目类别:
-
资助金额:$29.53万
-
财政年份:2004
-
负责人:LEROY F LIU
-
依托单位:
Mechanism of action of TOP2-directed anticancer drugs
-
批准号:7194334
-
项目类别:
-
资助金额:$27.2万
-
财政年份:2004
-
负责人:LEROY F LIU
-
依托单位:
Mechanism of action of TOP2-directed anticancer drugs
-
批准号:6868144
-
项目类别:
-
资助金额:$28.69万
-
财政年份:2004
-
负责人:LEROY F LIU
-
依托单位:
Mechanism of Action of TOP2-Directed Anticancer Drugs
-
批准号:8700947
-
项目类别:
-
资助金额:$6.58万
-
财政年份:2004
-
负责人:LEROY F LIU
-
依托单位:
Topoisomerase I-directed Anticancer Drugs
-
批准号:6687804
-
项目类别:
-
资助金额:$27.95万
-
财政年份:1998
-
负责人:LEROY F LIU
-
依托单位:
PROTOBERBERINES AS DUAL POISONS OF TOPOISOMERASES
-
批准号:6173399
-
项目类别:
-
资助金额:$22.6万
-
财政年份:1998
-
负责人:LEROY F LIU
-
依托单位:
Topoisomerase I-directed Anticancer Drugs
-
批准号:6621894
-
项目类别:
-
资助金额:$27.95万
-
财政年份:1998
-
负责人:LEROY F LIU
-
依托单位:
PROTOBERBERINES AS DUAL POISONS OF TOPOISOMERASES
-
批准号:2896423
-
项目类别:
-
资助金额:$21.94万
-
财政年份:1998
-
负责人:LEROY F LIU
-
依托单位:
PROTOBERBERINES AS DUAL POISONS OF TOPOISOMERASES
-
批准号:2592795
-
项目类别:
-
资助金额:$21.3万
-
财政年份:1998
-
负责人:LEROY F LIU
-
依托单位:
海外基金